<DOC>
	<DOCNO>NCT02027090</DOCNO>
	<brief_summary>We hypothesize high dose icotinib relate well efficacy . The primary objective compare progression-free survival high dose routine dose icotinib treat pretreated advanced non-small cell lung cancer patient stable disease 8-week routine dose icotinib treatment .</brief_summary>
	<brief_title>High Dose Versus Routine Dose Icotinib Advanced Non-small Cell Lung Cancer Patients With Stable Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Histologically cytologically confirm stage IIIB/IV lung cancer ( exclude patient confirm sputum cytology ) ; Pretreated least 1 platinumbased chemotherapy ; No previous target treatment gefitinib , erlotinib ; With measurable disease ( long diameter &gt; =10mm Spiral compute tomography ( CT ) &gt; =20mm conventional CT ) accord RECIST Criteria ; WHO performance status ( PS ) &lt; = 2 ; Adequate organ function ; Signed date informed consent start specific protocol procedure . Allergic icotinib ; Patients metastatic brain tumor symptoms ; Experience AntiEGFR ( epidermal growth factor receptor ) Monoclonal Antibody small molecular compound therapy gefitinib , erlotinib Cetuximab ; Severe systemic disease control unstable uncompensated respiratory , cardiac , liver , renal disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>